[1]
Ajikumar B Aryangat and John E Gerich 2010. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vascular Health and Risk Management. 6, (2010).
[2]
Anderson, B. et al. 2005. The art of empowerment: stories and strategies for diabetes educators. American Diabetes Association.
[3]
Ashwell, S.G. et al. 2006. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine. 23, 3 (Mar. 2006), 285–292. DOI:https://doi.org/10.1111/j.1464-5491.2005.01781.x.
[4]
Bergenstal, R.M. et al. 2010. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine. 363, 4 (Jul. 2010), 311–320. DOI:https://doi.org/10.1056/NEJMoa1002853.
[5]
Bolinder, J. et al. 2016. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. The Lancet. 388, 10057 (Nov. 2016), 2254–2263. DOI:https://doi.org/10.1016/S0140-6736(16)31535-5.
[6]
Bretzel, R.G. et al. 2008. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. The Lancet. 371, 9618 (Mar. 2008), 1073–1084. DOI:https://doi.org/10.1016/S0140-6736(08)60485-7.
[7]
Buse, J.B. et al. 2011. Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine. 154, 2 (Jan. 2011). DOI:https://doi.org/10.7326/0003-4819-154-2-201101180-00300.
[8]
Carver, C. 2006. Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. The Diabetes Educator. 32, 6 (Nov. 2006), 910–917. DOI:https://doi.org/10.1177/0145721706294259.
[9]
Crasto, W. et al. 2009. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgraduate Medical Journal. 85, 1002 (Apr. 2009), 219–222. DOI:https://doi.org/10.1136/pgmj.2008.073379.
[10]
Daly, H. et al. 2015. Development of a self-management education module for those with type 2 diabetes on injectable therapies. Practical Diabetes. 32, 8 (Oct. 2015), 305–310a. DOI:https://doi.org/10.1002/pdi.1979.
[11]
Davies, M. et al. 2005. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care. 28, 6 (Jun. 2005), 1282–1288. DOI:https://doi.org/10.2337/diacare.28.6.1282.
[12]
Davies, M.J. et al. 2009. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism. 11, 12 (Dec. 2009), 1153–1162. DOI:https://doi.org/10.1111/j.1463-1326.2009.01154.x.
[13]
Davies, M.J. et al. 2009. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism. 11, 12 (Dec. 2009), 1153–1162. DOI:https://doi.org/10.1111/j.1463-1326.2009.01154.x.
[14]
Davies, M.J. et al. 2017. Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. Diabetes, Obesity and Metabolism. (Apr. 2017). DOI:https://doi.org/10.1111/dom.12980.
[15]
Diamant, M. et al. 2010. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet. 375, 9733 (Jun. 2010), 2234–2243. DOI:https://doi.org/10.1016/S0140-6736(10)60406-0.
[16]
Evans, M. et al. 2011. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism. 13, 8 (Aug. 2011), 677–684. DOI:https://doi.org/10.1111/j.1463-1326.2011.01395.x.
[17]
Frandsen, C.S.S. and Madsbad, S. 2014. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine. 31, 11 (Nov. 2014), 1293–1300. DOI:https://doi.org/10.1111/dme.12561.
[18]
Funnell, M.M. 2007. Overcoming Barriers to the Initiation of Insulin Therapy. Clinical Diabetes. 25, 1 (Jan. 2007), 36–38. DOI:https://doi.org/10.2337/diaclin.25.1.36.
[19]
Garber, A.J. et al. 2006. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism. 8, 1 (Jan. 2006), 58–66. DOI:https://doi.org/10.1111/j.1463-1326.2005.00563.x.
[20]
Garber, A.J. et al. 2007. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes, Obesity and Metabolism. 9, 5 (Sep. 2007), 630–639. DOI:https://doi.org/10.1111/j.1463-1326.2006.00654.x.
[21]
Gough, S.C.L. 2007. A review of human and analogue insulin trials. Diabetes Research and Clinical Practice. 77, 1 (Jul. 2007), 1–15. DOI:https://doi.org/10.1016/j.diabres.2006.10.015.
[22]
Gough, S.C.L. et al. 2013. Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes. Diabetes Care. 36, 9 (Sep. 2013), 2536–2542. DOI:https://doi.org/10.2337/dc12-2329.
[23]
Gururaj Setty, S. et al. 2016. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal. 92, 1085 (Mar. 2016), 152–164. DOI:https://doi.org/10.1136/postgradmedj-2015-133716.
[24]
Gururaj Setty, S. et al. 2016. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal. 92, 1085 (Mar. 2016), 152–164. DOI:https://doi.org/10.1136/postgradmedj-2015-133716.
[25]
Heller, S.R. et al. 2004. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabetic Medicine. 21, 7 (Jul. 2004), 769–775. DOI:https://doi.org/10.1111/j.1464-5491.2004.01244.x.
[26]
Hermansen, K. et al. 2006. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care. 29, 6 (Jun. 2006), 1269–1274. DOI:https://doi.org/10.2337/dc05-1365.
[27]
Hirsch, I.B. et al. 2014. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism. 16, 3 (Mar. 2014), 206–214. DOI:https://doi.org/10.1111/dom.12136.
[28]
Hirsch, I.B. et al. 2014. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism. 16, 3 (Mar. 2014), 206–214. DOI:https://doi.org/10.1111/dom.12136.
[29]
Hirsch, I.B. et al. 2017. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). Diabetic Medicine. 34, 2 (Feb. 2017), 167–173. DOI:https://doi.org/10.1111/dme.13068.
[30]
Holman, R.R. et al. 2007. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine. 357, 17 (Oct. 2007), 1716–1730. DOI:https://doi.org/10.1056/NEJMoa075392.
[31]
Holman, R.R. and Turner, R.C. 1985. A Practical Guide to Basal and Prandial Insulin Therapy. Diabetic Medicine. 2, 1 (Jan. 1985), 45–53. DOI:https://doi.org/10.1111/j.1464-5491.1985.tb00592.x.
[32]
Home, P.D. 2012. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism. 14, 9 (Sep. 2012), 780–788. DOI:https://doi.org/10.1111/j.1463-1326.2012.01580.x.
[33]
Horvath, K. et al. 1996. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.
[34]
Horvath, K. et al. 1996. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.
[35]
Htike, Z.Z. et al. 2017. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. (Feb. 2017). DOI:https://doi.org/10.1111/dom.12849.
[36]
Inzucchi, S.E. et al. 2015. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 38, 1 (Jan. 2015), 140–149. DOI:https://doi.org/10.2337/dc14-2441.
[37]
Ismail-Beigi, F. 2012. Glycemic Management of Type 2 Diabetes Mellitus. New England Journal of Medicine. 366, 14 (Apr. 2012), 1319–1327. DOI:https://doi.org/10.1056/NEJMcp1013127.
[38]
June James Safety and insulin: implementation of national guidance at a local level. Journal of diabetes nursing.
[39]
Khunti, K. et al. 2015. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care. 38, 2 (Feb. 2015), 316–322. DOI:https://doi.org/10.2337/dc14-0920.
[40]
L. Luzi 1989. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. American Journal of Physiology - Endocrinology and Metabolism. 257, 2 (Aug. 1989), E241–E246.
[41]
Leelarathna, L. et al. 2017. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. Diabetic Medicine. 34, 10 (Oct. 2017), 1372–1379. DOI:https://doi.org/10.1111/dme.13412.
[42]
Luc JC van Loon 2000. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. The American Journal of Clinical Nutrition. 72, 1 (Jan. 2000), 96–105.
[43]
MacKinnon, M. 2002. Providing diabetes care in general practice: a practical guide to integrated care. Class.
[44]
Mäkimattila, S. et al. 1999. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia. 42, 4 (Mar. 1999), 406–412. DOI:https://doi.org/10.1007/s001250051172.
[45]
Malmberg, K. 1997. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 314, 7093 (May 1997), 1512–1512. DOI:https://doi.org/10.1136/bmj.314.7093.1512.
[46]
Marre, M. et al. 2009. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Medicine. 26, 3 (Mar. 2009), 268–278. DOI:https://doi.org/10.1111/j.1464-5491.2009.02666.x.
[47]
Marso, S.P. et al. 2017. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine. (Jun. 2017). DOI:https://doi.org/10.1056/NEJMoa1615692.
[48]
Menting, J.G. et al. 2013. How insulin engages its primary binding site on the insulin receptor. Nature. 493, 7431 (Jan. 2013), 241–245. DOI:https://doi.org/10.1038/nature11781.
[49]
Nathan, D.M. et al. 2006. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 29, 8 (Aug. 2006), 1963–1972. DOI:https://doi.org/10.2337/dc06-9912.
[50]
Nauck, M. 2016. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism. 18, 3 (Mar. 2016), 203–216. DOI:https://doi.org/10.1111/dom.12591.
[51]
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes: http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/.
[52]
Pickup, J.C. et al. 2017. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. Diabetes Care. 40, 5 (May 2017), 715–722. DOI:https://doi.org/10.2337/dc16-2201.
[53]
Raccah, D. et al. 2017. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. (Jun. 2017). DOI:https://doi.org/10.1111/dme.13390.
[54]
Raccah, D. et al. 2017. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. 34, 9 (Sep. 2017), 1193–1204. DOI:https://doi.org/10.1111/dme.13390.
[55]
Raskin, P. et al. 2005. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care. 28, 2 (Feb. 2005), 260–265. DOI:https://doi.org/10.2337/diacare.28.2.260.
[56]
Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. - PubMed - NCBI: http://www.ncbi.nlm.nih.gov/pubmed/18715200.
[57]
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.
[58]
Richter, B. and Neises, G. 1996. ‘Human’ insulin versus animal insulin in people with diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.
[59]
Riddle, M.C. et al. 2013. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. Diabetes Care. 36, 9 (Sep. 2013), 2489–2496. DOI:https://doi.org/10.2337/dc12-2454.
[60]
Rodbard, H.W. et al. 2017. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabetic Medicine. 34, 2 (Feb. 2017), 189–196. DOI:https://doi.org/10.1111/dme.13256.
[61]
Rorsman, P. and Renstr�m, E. 2003. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 46, 8 (Aug. 2003), 1029–1045. DOI:https://doi.org/10.1007/s00125-003-1153-1.
[62]
Rosenstock, J. et al. 2008. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 51, 3 (Mar. 2008), 408–416. DOI:https://doi.org/10.1007/s00125-007-0911-x.
[63]
Rosenstock, J. et al. 2013. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 36, 10 (Oct. 2013), 2945–2951. DOI:https://doi.org/10.2337/dc12-2709.
[64]
Rosenstock, J. et al. 2014. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care. 37, 7 (Jul. 2014), 1815–1823. DOI:https://doi.org/10.2337/dc13-3055.
[65]
Sharon Allard,Caroline Butler,Sue Cradock,Heather Daly,Jemma Edwards,Elizabeth Gilbert 2010. Using Conversation Maps in practice: the UK experience. Journal of Diabetes Nursing. 14, 1 (2010).
[66]
Srinivasan, B.T. et al. 2008. Recent advances in the management of type 2 diabetes mellitus: a review. Postgraduate Medical Journal. 84, 996 (Oct. 2008), 524–531. DOI:https://doi.org/10.1136/pgmj.2008.067918.
[67]
Srinivasan, B.T. and Davies, M. 2014. Glycaemic management of type 2 diabetes. Medicine. 42, 12 (Dec. 2014), 711–717. DOI:https://doi.org/10.1016/j.mpmed.2014.09.011.
[68]
Swinnen, S.G. et al. 1996. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.
[69]
Villani, M. et al. 2017. Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine. 34, 9 (Sep. 2017), 1205–1211. DOI:https://doi.org/10.1111/dme.13379.
[70]
Wahren, J. and Kallas, A. 2012. Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? Diabetes. 61, 9 (Sep. 2012), 2228–2229. DOI:https://doi.org/10.2337/db12-0664.
[71]
Walker, R.A. et al. 2010. Diabetes: a practical guide to managing your health. Dorling Kindersley.
[72]
Wang, W. et al. 2017. Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy. (Jun. 2017). DOI:https://doi.org/10.1007/s13300-017-0282-3.
[73]
Yki-Järvinen, H. et al. 2006. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 49, 3 (Mar. 2006), 442–451. DOI:https://doi.org/10.1007/s00125-005-0132-0.
[74]
Young, L.A. and Buse, J.B. 2014. GLP-1 receptor agonists and basal insulin in type 2 diabetes. The Lancet. 384, 9961 (Dec. 2014), 2180–2181. DOI:https://doi.org/10.1016/S0140-6736(14)61409-4.
[75]
Zinman, B. et al. 2011. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet. 377, 9769 (Mar. 2011), 924–931. DOI:https://doi.org/10.1016/S0140-6736(10)62305-7.
[76]
4AD. Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes.
